Anal Cancer News and Research RSS Feed - Anal Cancer News and Research

Anal cancer is a type of cancer which arises from the anus, the distal orifice of the gastrointestinal tract. It is a distinct entity from the more common colorectal cancer.
Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round. [More]
Moffitt researchers find cancer healthcare disparities in LGBTQ community

Moffitt researchers find cancer healthcare disparities in LGBTQ community

The Lesbian, Gay, Bisexual, Transgender/Transsexual, Queer/Questioning (LGBTQ) community is a growing and medically-underserved minority population in the United States, with 3 to 12 percent of the population estimated to identify as LGBTQ. [More]
FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer. [More]
PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients. [More]
Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck, known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada. [More]
HPV vaccine does not increase rates of STIs in adolescent females

HPV vaccine does not increase rates of STIs in adolescent females

Receiving the human papillomavirus vaccine does not increase rates of sexually transmitted infections (STIs) in adolescent females. The vaccine, which can prevent cervical cancer in women, has had a low uptake, partly because of concerns about how it will affect adolescent sexual activity. [More]
Japanese mushroom extract shows promise in eradicating HPV

Japanese mushroom extract shows promise in eradicating HPV

A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School. [More]
Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix. [More]
Research team to investigate ways to develop novel immune therapies for HPV-associated cancers

Research team to investigate ways to develop novel immune therapies for HPV-associated cancers

Stand Up To Cancer and the Farrah Fawcett Foundation, along with the American Association for Cancer Research, SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9. [More]
SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9. [More]
Japanese mushroom extract active hexose correlated compound (AHCC) may have role in prevention HPV-related cancers

Japanese mushroom extract active hexose correlated compound (AHCC) may have role in prevention HPV-related cancers

... [More]
First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors. [More]
Older HIV-positive men at higher risk of HPV that causes anal cancer

Older HIV-positive men at higher risk of HPV that causes anal cancer

Human papillomavirus, or HPV, which can cause cervical cancer in women, is also known to cause anal cancer in both women and men. Now, a study led by researchers at the UCLA School of Nursing has found that older HIV-positive men who have sex with men are at higher risk of becoming infected with the HPVs that most often cause anal cancer. [More]
Philadelphia hospital reaches out to homeless

Philadelphia hospital reaches out to homeless

The program helps reinforce the importance of health care for shelter residents and their children. [More]
HPV vaccine coverage among teens still remains low than other recommended vaccinations

HPV vaccine coverage among teens still remains low than other recommended vaccinations

Barriers to human papillomavirus (HPV) vaccination among adolescents in the U.S. range from financial concerns and parental attitudes to social influences and concerns about the vaccination's effect on sexual behavior, according to a review of the available medical literature published by JAMA Pediatrics, a JAMA Network publication. [More]
UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV. [More]

Research reveals that HPV infection is associated with higher subsequent risk of HIV infection

A study of 2,519 Kenyan men conducted by researchers at the University of North Carolina revealed that infection with the human papillomavirus (HPV) was associated with a higher subsequent risk of infection with HIV, a precursor to AIDS. [More]

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia. [More]
FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Advaxis, Inc., (OTCQB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer. [More]
p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer. [More]
Advertisement
Advertisement